News
-
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation -
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments -
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need -
